The ZIM Health Technologies Limited (ZHTL) team has been pivotal in enhancing the growth of ZIM’s business and product pipeline over the last few years. During FY22, with the active involvement of the ZHTL team, the R&D team at ZIM has developed new innovative products and filed dossiers for registrations across various geographies. The ZHTL Team has been instrumental in advising the management of ZIM on enhancing operational efficiency.
ZIM Health Technologies Limited (ZHTL), a wholly owned subsidiary of ZIM Laboratories, operates as an extended research and development unit. The company specializes in pharmaceutical trading and provides research consulting services.
ZIM Health Technologies Limited (ZHTL), a wholly-owned subsidiary, serves as an expanded research and development arm aimed at bolstering ZIM’s efforts in product development, manufacturing, and marketing of sophisticated generic and high-end pharmaceutical and nutraceutical products. Its focus lies particularly on catering to Developed and Pharmerging markets.
